Identification of the Wnt signaling pathway and discovery that a loss of function of sclerostin is responsible for high bone mass diseases, such as sclerosteosis or Van Buchem disease, have promoted sclerostin as a potential therapeutic target for increasing bone formation, in osteoporosis or other bone diseases. Here, SOST is linked to sclerosteosis.